[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai General Hospital, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":188},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,67,92,122,145,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100646684","multicenter-randomized-controlled-trial-of-thulep-versus-thulep-combined-with-bladder-neck-incision-in-patients-with-small-volume-benign-prostatic-hyperplasia-100646684",false,"NCT07688447","Multicenter Randomized Controlled Trial of ThuLEP Versus ThuLEP Combined With Bladder Neck Incision in Patients With Small-Volume Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Male patients aged 50-85 years who meet the diagnostic criteria for benign prostatic hyperplasia (BPH), with a prostate volume ≤30 mL and requiring surgical intervention.\n* Preoperative International Prostate Symptom Score (IPSS) ≥8.\n* Preoperative maximum urinary flow rate (Qmax) ≤15 mL\u002Fs.\n* Bladder capacity ≥150 mL.\n* Willing to participate in this clinical trial and has signed the informed consent form.\n* Able to communicate well with investigators and comply with the study protocol requirements.\n\nExclusion Criteria:\n\n* Patients with urethral stricture in whom passage of surgical instruments is not feasible.\n* Total PSA \\>10 ng\u002FmL, or PSA between 4-10 ng\u002FmL with a free-to-total PSA ratio \\\u003C0.16, and confirmed malignancy on biopsy.\n* Coagulation disorders, including platelet count \\\u003C80 × 10⁹\u002FL.\n* Uncontrolled urinary tract infection.\n* Neurogenic bladder.\n* Presence of malignant tumors.\n* Urodynamic diagnosis of bladder neck sclerosis, detrusor underactivity, detrusor-sphincter dyssynergia, or unstable bladder.\n* Contraindications to surgery, such as severe cardiopulmonary disease.\n* Cognitive impairment, including senile dementia, cerebral atrophy, acute cerebrovascular disease, sequelae of cerebrovascular disease, or other conditions affecting cognitive function.\n* History of suprapubic cystostomy for benign prostatic hyperplasia.\n* Acute localized or systemic bacterial infection that has not been effectively controlled.\n* Presence of shock or other critical conditions that preclude cooperation with the procedure and outcome evaluation.\n* Psychiatric or neurological disorders preventing cooperation with the study.\n* Participation in another clinical trial within 1 month prior to enrollment.\n* Any other condition deemed inappropriate for inclusion by the investigators.","MALE","50 Years","85 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","With the increasing degree of population aging, the number of patients undergoing surgical treatment for benign prostatic hyperplasia (BPH) is steadily rising. Among them, patients with small-volume prostates (≤30 mL) represent a distinct clinical subgroup.\n\nThis population has several unique characteristics:\n\n1. Approximately 17.5% of patients show suboptimal postoperative outcomes.\n2. The incidence of postoperative bladder neck contracture (BNC) is relatively high, reaching up to 19.3% in some reports.\n\nIn addition, the pathophysiological mechanisms of small-volume BPH are different from those of larger prostates. These include increased fibrotic tension of the bladder neck and bladder neck elevation.\n\nAt present, there is no clearly established surgical approach specifically designed to further improve postoperative outcomes or effectively prevent bladder neck contracture in patients with small-volume BPH.\n\nThis study primarily compares the safety and efficacy of transurethral thulium laser enucleation of the prostate (ThuLEP) versus ThuLEP combined with bladder neck incision in the treatment of small-volume benign prostatic hyperplasia (BPH), with the aim of further optimizing surgical management strategies for small prostates and reducing the incidence of postoperative complications.",[26],"Prostatic Hypertrophy, Benign",[28],"Prostatic Hypertrophy","RECRUITING","2026-07-30",{"date":32,"type":33},"2026-07-31","ACTUAL",{"date":35,"type":20},"2026-07-01",{"date":37,"type":20},"2027-12-31",{"name":39,"class":40},"Shanghai General Hospital, China","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100649397","phase-2-efficacy-and-safety-of-serplulimab-in-combination-with-bevacizumab-and-folfirinox-or-nalirifox-as-second-line-therapy-in-patients-with-metastatic-pancreatic-ductal-adenocarcinoma-100649397","NCT07733050","Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: An Open-Label, Single-Arm, Phase II Study","Inclusion Criteria:\n\n* Voluntary participation with signed written informed consent, good compliance, and willingness to adhere to follow-up visits.\n* Age ≥ 18 years, male or female.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 and life expectancy ≥ 3 months.\n* Histologically or cytologically confirmed locally advanced unresectable or metastatic pancreatic adenocarcinoma.\n* Must have received prior first-line (1L) systemic therapy. Prior neoadjuvant or adjuvant chemotherapy is allowed if the last treatment was administered \\> 6 months before disease recurrence\u002Fprogression.\n* No prior exposure to irinotecan or oxaliplatin.\n* At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Adequate major organ function, defined as follows:\n\nHematology: Hemoglobin ≥ 90 g\u002FL (no transfusion within 14 days); Absolute Neutrophil Count ≥ 1.5 × 10⁹\u002FL; Platelets ≥ 75 × 10⁹\u002FL.\n\nBiochemistry: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT and AST ≤ 3 × ULN (or ≤ 5 × ULN in the presence of liver metastases); Serum creatinine ≤ 1 × ULN with calculated creatinine clearance \\> 50 mL\u002Fmin (Cockcroft-Gault formula).\n\nCoagulation: International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN (or within therapeutic range for patients on stable anticoagulation).\n\nThyroid: Normal TSH, or abnormal TSH with normal FT3\u002FFT4 (e.g., controlled hypothyroidism).\n\nCardiac: QTc interval (Fridericia's formula) ≤ 450 ms for males and ≤ 470 ms for females.\n\n\\- Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to use effective contraception during the study and for 6 months after the last dose. Male participants with female partners of childbearing potential must agree to use effective contraception during the study and for 6 months after the last dose.\n\nExclusion Criteria:\n\n* Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibodies, or any other agents specifically targeting T-cell co-stimulation or immune checkpoint pathways.\n* Prior treatment with bevacizumab or other anti-angiogenic agents. Radiological evidence of major vascular tumor invasion or high risk of fatal hemorrhage; active gastrointestinal bleeding, persistent bleeding disorders, or coagulopathy.\n* Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, immunotherapy, or molecular targeted therapy within 4 weeks prior to the first dose (bisphosphonates for bone metastases are allowed).\n* Uncontrolled central nervous system (CNS) metastases (i.e., symptomatic or requiring corticosteroids or mannitol for symptom control).\n* Clinically significant or uncontrolled cardiac disease within 6 months prior to the first dose, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmias.\n* Persistent toxicities from prior therapy ≥ Grade 1 (per NCI-CTCAE v5.0), including Grade 1 peripheral neuropathy. Exceptions: alopecia or conditions deemed not exclusionary by the investigator (with clear documentation).\n* Other active malignancy within 5 years prior to the first dose, except for adequately treated basal cell carcinoma of the skin or cervical carcinoma in situ.\n* Active autoimmune disease requiring systemic treatment within 2 years prior to the first dose. Exceptions: vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis requiring only hormone replacement therapy.\n* History of immediate hypersensitivity reactions, eczema, or asthma not controlled by topical corticosteroids.\n* History of drug-induced interstitial lung disease (ILD), pneumonitis, obstructive pulmonary disease severely affecting lung function, or symptomatic bronchospasm.\n* Severe infection (\\> CTCAE Grade 2) requiring antibiotic therapy within 14 days prior to the first dose (e.g., severe pneumonia, bacteremia, infectious complications requiring hospitalization).\n* Receipt of live-attenuated vaccine within 4 weeks prior to the first dose, or planned vaccination during the study period.\n* Known human immunodeficiency virus (HIV) infection, history of allogeneic organ transplantation, or allogeneic hematopoietic stem cell transplantation.\n* History of allergy or hypersensitivity to any component or excipient of the investigational drugs.\n* Any other condition deemed by the investigator to be unsuitable for participation in the study.","ALL","18 Years",{"count":52,"type":20},34,[54],"PHASE2","This is an investigator-initiated, open-label, single-arm, phase II trial evaluating the efficacy and safety of serplulimab (an anti-PD-1 monoclonal antibody) plus bevacizumab, combined with either FOLFIRINOX or NALIRIFOX chemotherapy, as second-line treatment for metastatic pancreatic ductal adenocarcinoma. The study will enrol up to 34 patients.",[57],"Metastatic Pancreatic Ductal Adenocarcinoma","NOT_YET_RECRUITING","2026-07-28",{"date":61,"type":33},"2026-07-29",{"date":63,"type":20},"2026-08-01",{"date":65,"type":20},"2028-08-01",{"name":39,"class":40},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":49,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100614559","xinqiao-high-risk-cohort-of-diabetesnice-100614559","NCT07281170","Xinqiao High-risk Cohort of Diabetes(NICE)","Xinqiao High-risk Cohort of Diabetes","Inclusion Criteria:\n\n* Individuals who provide written informed consen\n* Have access to a smartphone\n* Hamily history of diabetes or abnormal microglucose level detected once\n* Age ≥18 years at the time of consent\n\nExclusion Criteria:\n\n* Diabetes mellitus\n* Any other condition which, in the judgment of the investigator, would make the subject unsuitable for enrollment in the study\n* recently surgical histories, trauma, acute cardiovascular complications, or infectious diseases","20 Months","79 Years",{"count":77,"type":20},7000,"OBSERVATIONAL","Objective: 1. To systematically screen the high-risk population of diabetes in Xinqiao area, understand the characteristics of early glucose metabolism changes and pancreatic islet function changes in the high-risk population and patients with prediabetes, and establish the first standardized research cohort of high-risk patients and prediabetes patients in Songjiang area.\n\n2\\. Use CGM monitoring technology to identify the high-risk groups of diabetes and the fluctuation of blood glucose in pre-diabetes, understand their ophthalmology and bone density, observe the annual conversion rate of diabetes, find effective interventions, move forward the management of diabetes, and create a new model for the management of high-risk groups of diabetes.\n\nResearch content: Part I: Establishing the first standardized diabetes high-risk population research cohort in Songjiang area The initiative focuses on early screening for high-risk populations with diabetes, shifting the focus downward and advancing prevention measures to detect diabetes at an earlier stage and initiate timely intervention. In Xinqiao District, all high-risk screening cases will undergo medical history documentation, anthropometric measurements, laboratory testing, and regular follow-ups. Standard oral glucose tolerance test (OGTT) methods will be employed to assess fasting blood glucose levels, insulin sensitivity, 2-hour postprandial glucose and insulin levels after a 75g glucose load, and glycated hemoglobin levels. Beyond evaluating glucose metabolism, the screening will also detect other metabolic disorders through routine blood tests including urinalysis, liver\u002Fkidney function tests, uric acid levels, lipid profiles, thyroid function, and urine protein\u002Fcreatinine ratio. The establishment of this premium high-risk screening program in Xinqiao Community will create Songjiang District's first standardized research cohort for diabetes mellitus (DM) and prediabetes patients, carrying significant strategic importance.\n\nPart II: By integrating Clinical Monitoring (CGM) technology with ophthalmological evaluations and bone density ultrasound examinations, we identify characteristics of high-risk diabetic populations and track their disease progression. The CGM system (with auxiliary devices such as the Shansheng Dynamic Glucose Monitoring System) is utilized to monitor blood glucose fluctuations in these individuals. Concurrently, comprehensive ophthalmic assessments-including visual acuity tests, intraocular pressure measurements, fundus photography, OCT scans, OCTA imaging, and SLO examinations-are conducted alongside bone density testing. Annual follow-up evaluations are performed to track clinical outcomes.\n\nResearch innovation points and expected results: Research innovation points:\n\nEstablish the first standardized research cohort of high-risk and pre-diabetic patients in Songjiang area; move forward the management of diabetes, and create a new management model for high-risk groups of diabetes.\n\nanticipated results\n\n1. Establish a new standardized diabetes high-risk population research cohort with large sample size.\n2. Observe the metabolic characteristics, blood glucose fluctuation, ophthalmic conditions and bone density of high-risk groups with diabetes.\n3. Find effective interventions to reduce the annual conversion rate of diabetes.",[81],"Pre Diabetic",[83,81,84],"xinqiao","NICE",{"date":61,"type":33},{"date":87,"type":33},"2019-10-08",{"date":89,"type":20},"2034-12-31",{"name":39,"class":40},2,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":4},"100612774","apos-associated-with-respiratory-viral-infections-before-and-during-early-pregnancy-100612774","NCT07257952","APOs Associated With Respiratory Viral Infections Before and During Early Pregnancy","An Observational Study on the Risk of Adverse Maternal and Infant Outcomes Associated With Respiratory Viral Infections Before and During Early Pregnancy","APO","Inclusion Criteria:\n\n* Female;\n* Age 20 to 45 years old;\n* Physician-diagnosed acute respiratory viral infection occurring within 6 months before pregnancy and\u002For at \\\u003C24 weeks of gestation.\n\nExclusion Criteria:\n\n* Pregestational T1D or T2D;\n* Long-term use of immunosuppressants or glucocorticoids;\n* Diseases that severely affect immune or metabolic function (e.g., HIV, SLE, rheumatoid arthritis);\n* Severe mental illness or cognitive impairment;\n* Women whose electronic medical records lack GDM screening and delivery records.","FEMALE","20 Years","45 Years",{"count":104,"type":20},1440,"Adverse pregnancy outcomes (APOs) are a collection of conditions that have short-term and long-term effects of complications related to pregnancy and childbirth on pregnant women and their fetuses, including hypertensive disorders of pregnancy, gestational diabetes, preterm birth, large for gestational age, among others. Nearly 30% of all women experience an adverse pregnancy outcome during their reproductive years. Although, respiratory viral infections with epidemic and pandemic potential pose an omnipresent threat to public health, research focusing specifically on the maternal-infant population remains relatively scarce.\n\nStudies conducted in USA found that among pregnant women infected with influenza, the proportion of those with gestational hypertension or diabetes was higher than in pregnant women without influenza infection (13.9% vs. 11.1%).\n\nResearch on the impact of respiratory viral infections on perinatal outcomes in China is limited, and we aim to establish of a large-scale, retroprospective maternal-child cohorts. This cohort study will systematically collect longitudinal data (e.g., detailed clinical history, timing of infection\u002Fvaccination, complication of pregnancy, and APOs) to assess the risk of respiratory viral infections to APOs, as well as facilitate multidisciplinary research.",[107,108],"Respiratory Viral Infections","Adverse Pregnancy Outcomes",[110,111,112,113],"Adverse pregnancy outcome","Preterm birth","Gestational diabetes mullitus","Respiratory Viral Infection","2026-04-21",{"date":116,"type":33},"2026-04-23",{"date":118,"type":20},"2026-07-05",{"date":120,"type":20},"2028-11-30",{"name":39,"class":40},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":49,"minAge":4,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":131,"conditions":132,"keywords":137,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":41},"100559651","monitoring-of-antimicrobial-resistance-based-on-metagenomics-analyses-in-pneumonia-patients-100559651","NCT06566898","Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients","Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients: a Genomic Epidemiology Study","Inclusion Criteria:\n\n* Patients clinically diagnosed as severe pneumonia and mild pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), who meet 1 of the following major criteria or ≥3 minor criteria can be diagnosed. The diagnostic criteria for severe and mild pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011.\n* Clinical examination was performed, and there was biospecimen (nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage fluid, sputum, blood, hydrothorax, lung tissue) remaining in the clinical microbiological examination.\n\nExclusion Criteria:\n\n* Patients whose biological samples may be contaminated;\n* Patients with alveolar lavage fluid or hydrothorax volume less than 200μl.",{"count":130,"type":20},800,"Monitoring of antimicrobial resistance (AMR) based on metagenomics analyses in pneumonia patients is critical for optimizing clinical diagnosis and treatment and improving clinical prognosis. This study is designed to ask the following key questions:\n\n1. What is the microbiome maps of patients with severe pneumonia and mild pneumonia ?\n2. How many pathogen resistance genes are carrying in severe pneumonia and mild pneumonia ?\n3. What is the genetic diversity of key pathogens detected in severe pneumonia and mild pneumonia during 2019-2025?",[133,134,135,136],"Pneumonia","Next-generation Sequencing","Microbiome","Antimicrobial Resistance",[133,138,135,136],"Next-generation sequencing",{"date":116,"type":33},{"date":141,"type":33},"2024-08-01",{"date":143,"type":20},"2026-09-30",{"name":39,"class":40},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":100,"minAge":50,"maxAge":4,"enrollmentInfo":153,"targetDuration":155,"studyType":78,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":166,"locationsCount":41},"100605394","shanghai-clinical-cohort-of-hyperglycemia-in-pregnancy-100605394","NCT07161947","Shanghai Clinical Cohort of Hyperglycemia in Pregnancy","Shanghai Clinical Cohort-Hyperglycemia in Pregnancy (Reserved)","SHINE","Inclusion Criteria:\n\n* Pregnant individuals who provide written informed consent\n* At enrollment, meet one of the following:\n\n  1\\. Gestational diabetes mellitus (GDM) diagnosed by a 75-g oral glucose tolerance test (OGTT) using Chinese Diabetes Society (CDS) 2024 thresholds (any one of: fasting plasma glucose ≥5.1 mmol\u002FL, 1-h ≥10.0 mmol\u002FL, or 2-h ≥8.5 mmol\u002FL); or 2. Pre-gestational diabetes (type 1 or type 2) documented prior to pregnancy or meeting diabetes criteria at the first prenatal visit (e.g., fasting ≥7.0 mmol\u002FL, 2-h OGTT ≥11.1 mmol\u002FL, or HbA1c ≥6.5%); or 3. At high risk for GDM, defined a priori as ≥1 of the following: prior GDM; prior macrosomic infant (≥4,000 g); pre-pregnancy BMI ≥24 kg\u002Fm²; age ≥45 years; high-density lipoprotein cholesterol \\\u003C1 mmol\u002FL, and\u002For triglyceride levels \\>2.8 mmol\u002FL; first-degree family history of diabetes; polycystic ovary syndrome (PCOS); history of coronary heart disease; chronic hypertension and repeated positive fasting urinary glucose in early pregnancy\n* Age ≥18 years at the time of consent\n* Willing and able to attend postpartum assessments (OGTT at 6 weeks, 12 months, and annually thereafter), with planned follow-up ≥3 years\n\nExclusion Criteria:\n\n* Current or history of illicit drug use or substance abuse\n* Presence of an active infectious disease, including but not limited to: viral hepatitis, sexually transmitted infections or tuberculosis\n* Any other condition which, in the judgment of the investigator, would make the subject unsuitable for enrollment in the study",{"count":154,"type":20},4000,"10 Years","Establish a high-quality clinical cohort of hyperglycemia in pregnancy. Develop subtype-specific, end-to-end standards for diagnosis, treatment, and follow-up across the preconception, pregnancy, and postpartum phases. These standards will lay a solid foundation for efficient, high-quality clinical research.",[158,159],"Hyperglycemia in Pregnant Diabetic Patients","Gestatiaonl Diabetes Mellitus","2025-09-08",{"date":162,"type":33},"2025-09-09",{"date":164,"type":33},"2025-04-01",{"date":37,"type":20},{"name":39,"class":40},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":100,"minAge":50,"maxAge":16,"enrollmentInfo":175,"targetDuration":155,"studyType":78,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":41},"100602620","gongji-pregnancy-endorine-cohort-study-100602620","NCT07125885","Gongji Pregnancy Endorine Cohort Study","Serological, Metabolomic, and Genomic Studies of Endocrine Disorders in Pregnancy","GREAT","Inclusion Criteria:\n\n* Women preparing for pregnancy or pregnant women or within 1 year after giving birth\n* Age ≥ 18 years old\n* Signed the informed consent form to voluntarily enroll in the management follow-up\n\nExclusion Criteria:\n\n* Individuals who are unable to communicate normally and those who are unwilling to cooperate\n* Pregnant women with severe organic diseases or mental illnesses\n* Any condition deemed by the investigator to affect eligibility for the study",{"count":176,"type":20},3000,"To explore the relationship between genetic factors, lifestyle, and drug interventions and the occurrence, development, adverse pregnancy outcomes, and postpartum maternal-infant outcomes of gestational endocrine diseases.",[159,179,158],"Thyroid Disease Pregnancy","2025-08-09",{"date":182,"type":33},"2025-08-15",{"date":184,"type":33},"2023-05-05",{"date":186,"type":20},"2043-12-31",{"name":39,"class":40},""]